Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
May 18th, 2008
Delcath Systems, Inc. (NASDAQ:DCTH) announced that the Institutional Review Board (IRB) of the University of Maryland Medical Center (UMMC) has approved UMMC's participation in the Phase III study of the Company's Percutaneous Hepatic Perfusion (PHP) System for the isolated, high dose delivery of the anti-cancer agent melphalan to treat inoperable metastatic melanoma in the liver. The pivotal, Phase III study is being led by the National Cancer Institute (NCI), which previously approved the study's expansion to a multi-center trial. UMMC has also entered into a clinical research agreement with Delcath enabling the hospital to immediately begin recruiting and treating...
Source: Medical Letter on the CDC & FDA (2008-05-18)
|
